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Swadling et al. show that an increased
rate of basal autophagy is a hallmark of
intrahepatic lymphocytes, particularly
liver-resident CD8+ T cells and that in vitro
TRM programming requires autophagy
induction. Upregulation of autophagy
adapts CD8+ T cells to combat
mitochondrial depolarization, optimize
functionality, and acquire tissue
residence.
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https://doi.org/10.1016/j.celrep.2019.12.050SUMMARY
Tissue-resident memory T cells have critical roles in
long-term pathogen and tumor immune surveillance
in the liver. We investigate the role of autophagy in
equipping human memory T cells to acquire tissue
residence and maintain functionality in the immuno-
suppressive liver environment. By performing
ex vivo staining of freshly isolated cells from human
liver tissue, we find that an increased rate of basal
autophagy is a hallmark of intrahepatic lymphocytes,
particularly liver-resident CD8+ T cells. CD8+ T cells
with increased autophagy are those best able to
proliferate and mediate cytotoxicity and cytokine
production. Conversely, blocking autophagy induc-
tion results in the accumulation of depolarized mito-
chondria, a feature of exhausted T cells. Primary he-
patic stellate cells or the prototypic hepatic cytokine
interleukin (IL)-15 induce autophagy in parallel with
tissue-homing/retention markers. Inhibition of T cell
autophagy abrogates tissue-residence program-
ming. Thus, upregulation of autophagy adapts
CD8+ T cells to combat mitochondrial depolarization,
optimize functionality, and acquire tissue residence.
INTRODUCTION
The liver has a distinct tolerogenic immune environment that is
exploited by hepatotropic infections and primary and metastatic
tumors. With deaths from viral hepatitis now exceeding those re-
sulting from tuberculosis and HIV (Graber-Stiehl, 2018), and pri-
mary liver cancer predicted to rise to the 13th leading cause of
death worldwide by 2040 (Foreman et al., 2018), it is essential
that we gain a better understanding of liver immunity to aid
development of immunotherapies.
T cells have an important role in clearing virus-infected and
cancerous cells, but they require tight regulation to avoid immu-
nopathology. Many T cell-tolerizing mechanisms are present in
the liver (reviewed in Maini and Pallett, 2018) to avoid an exces-Cell
This is an open access article undsive immune response to the constant flow of microbial products
and diet-derived antigens entering the liver from the gut via the
portal vein (Protzer et al., 2012). The liver is also unique in that
most of its blood supply is venous and, therefore, relatively low
in oxygen and flow rate when compared with arterial blood (re-
viewed in Carreau et al., 2011), and key T cell metabolites may
be depleted within the liver microvasculature (Pallett et al.,
2015; Das et al., 2008). However, little is known about the
T cell-intrinsic adaptations required to survive and retain func-
tionality in the liver.
We have recently defined a population of CD8+ tissue-resident
memory T (TRM) cells, which reside in the liver without recirculat-
ing through the blood and that are preferentially expanded in
patients with well-controlled hepatitis B virus (HBV) infection
(Pallett et al., 2017). Liver-resident TRM cells have a distinct
phenotype, transcription factor expression, and the capacity
to maintain efficient interleukin (IL)-2 and interferon (IFN)-g
production in the tolerogenic liver, but the cellular processes
and metabolic state driving these adaptations have not been
defined (Fernandez-Ruiz et al., 2016; Tse et al., 2011).
One constitutive, but highly dynamic, cellular process that all
cells require and that is regulated to maintain homeostasis under
cellular stress is macroautophagy (subsequently referred to
here as ‘‘autophagy’’). Autophagy is a highly conserved, lyso-
some-mediated, intracellular bulk-recycling process (Clarke
and Simon, 2019). The nucleation of double-membrane vesicles,
called autophagosomes, facilitates engulfment of a portion of
the cytoplasm for delivery to the lysosome for degradation
(Clarke and Simon, 2019). Autophagy has two main roles: first,
it allows cells to maintain their cellular homeostasis by removing
unwanted cytoplasmic content (pathogens, protein aggregates,
damaged organelles, and reactive oxygen species [ROS]);
and second, it provides biomolecules for cellular metabolism
through the catabolism of proteins and complex lipids. The
importance of this cellular process to diverse human T cell
memory subsets, including TRM cells, is not known.
Here, we address the hypothesis that liver-resident T cells use
higher constitutive autophagy levels to maintain homeostasis
in the liver. We characterize autophagy levels in human memory
T cell subsets, including liver-resident T cells and HBV-specific
T cells. Making use of our regular access to fresh human liverReports 30, 687–698, January 21, 2020 ª 2019 The Author(s). 687
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samples, we show that intrahepatic lymphocytes have a higher
ex vivo level of autophagy, with lymphocytes that reside in the
liver showing the highest rates of autophagy (TRM cells and
mucosal-associated invariant T cells [MAITs]). Recirculating
T cells specific for the hepatotropic infection HBV also show
high levels of autophagy. Recently activated, proliferating, or
highly functional T cells have enhanced rates of autophagy,
and maintenance of mitochondrial fitness is lost upon treatment
with autophagy inhibitors. Finally, we show that the prototypical
liver cytokine IL-15, required for the induction of liver-resident
T cells, can also upregulate T cell autophagy, whereas blockade
of autophagy abrogates TRM cell programming of CD8
+ T cells.
RESULTS
Higher Ex Vivo Autophagy Levels Are Characteristic of
Intrahepatic Lymphocytes
To measure autophagy in human T cells, we employed an estab-
lished flow-cytometry-based assay (FlowCellect autophagy LC3
antibody-based kit, Merck Millipore/Luminex; Eng et al., 2010)
that has been previously applied to human and murine lympho-
cyte subsets (O’Sullivan et al., 2016; Clarke et al., 2018), in
particular, T cells (Puleston et al., 2014; Kabat et al., 2016; Sand-
erson and Simon, 2017). A reliable and specific marker of
autophagic vesicles (autophagosomes) is LC3 (microtubule-
associated protein 1 light chain 3)—a cytosolic protein that is
lipidated and then incorporated into de novo-generated auto-
phagosomes (Klionsky et al., 2016). To assay basal autophagy
levels, cells are selectively permeabilized to extract cytosolic
LC3-I; then autophagosome-bound LC3-II is detected using a
fluorescently labeled anti-LC3 antibody (‘‘unblocked’’; see
Method Details). We also measured the accumulation of auto-
phagosomes over time by inhibiting autophagosome breakdown
with bafilomycin A1 (bafA1), an endosomal acidification inhibitor
(Klionsky et al., 2016; ‘‘blocked data’’). Finally, as a proxy for
autophagic flux and to eliminate the variation in the number of
autophagosomes at baseline (including tissue-specific variation
and cell size), we calculated the ratio of LC3 staining for blocked
versus unblocked samples.
We first investigated whether lymphocytes that have been
exposed to the tolerogenic liver microenvironment display a
different level of autophagy to peripheral lymphocytes isolated
from blood. To do so, we assayed the level of autophagy in
human intrahepatic lymphocytes (IHLs) from explanted liver
samples, liver perfusates, and paired blood (peripheral blood
mononuclear cells [PBMCs]). To observe the relative autophagy
levels of all lymphocyte subsets from paired PBMCand IHL sam-
ples, we performed dimension reduction by tSNE (t-distributed
stochastic neighbor embedding) on multiparametric flow cytom-
etry data to visualize the relative LC3 intensity of each cell.
PBMCs and IHLs showed overlapping distributions, but overall,
the intensity of LC3 staining was greater on IHLs (Figure 1A;
gating and example plots in Figure S1A). Several clusters of lym-
phocytes with high-intensity LC3 staining were uniquely
observed in IHL samples. We, therefore, extended this analysis
to a larger cohort of paired human blood and liver samples. Intra-
hepatic T cells had a significantly higher ex vivo level of auto-
phagy than T cells isolated from blood when gating on CD4+,688 Cell Reports 30, 687–698, January 21, 2020CD8+, or total CD3+ T cells (Figure 1B; unblocked data [no
bafA1] and blocked/unblocked ratio in Figures S1B and S1C,
respectively). Although autophagy levels increased with T cell
granularity (SSC [side scatter]), they did not directly correlate
with T cell size (FSC [forward scatter]), and enhanced ex vivo
autophagy levels were not higher because of T cells showing a
different morphology in the liver (Figure S1A). Differences in
autophagy levels between blood and liver were also not attribut-
able to differences in sample processing because they were
maintained when IHLs isolated from perfusion fluid of healthy
transplant livers, which are processed identically to blood,
were used (Figure S1D).
MAITs (CD161hi Va7.2+), a population of T cells that has
recently been shown to reside long term in the liver (Salou
et al., 2019), also had higher levels of autophagywhen compared
with CD161mid or CD161 T cells in the blood or liver, with each
of these subsets having higher LC3 levels in the liver than their
circulating counterparts (Figure 1C). Other lymphocytes assayed
also had a higher level of autophagy in the liver when compared
with the equivalent population in the blood, including CD19+ B
cells (Figure 1D). CD56+ natural killer (NK) cells were the excep-
tion, where autophagy levels were comparable between periph-
eral and intrahepatic populations (Figure 1D). Overall, several
lymphocyte subsets isolated from the liver had a higher level of
autophagy than their counterparts isolated from blood, in partic-
ular, T cells.
Enhanced Autophagy by Intrahepatic T Cells Is Not a
Result of a Difference in T Cell Memory Subset
Frequency or Recent Proliferation
We investigated whether the difference in T cell autophagy levels
in the liver and blood was due to a different T cell subset compo-
sition in the two compartments. In both IHLs and PBMCs, CD8+
T cells with an effector memory (TEM, CCR7
CD45RA) or cen-
tral memory (TCM; CCR7
+CD45RA) phenotype had the highest
level of autophagy, with naive (CCR7+CD45RA+) and terminally
differentiated effector memory (TEMRA; CCR7
CD45RA+; Sal-
lusto et al., 1999) T cells showing lower levels (Figure 2A). The
liver is enriched for memory T cells and has few naive T cells rela-
tive to blood (Pallett et al., 2017); however, all T cell subsets had a
higher level of autophagy in the liver, indicating that differences
between these compartments were not purely due to a different
balance of T cell memory subsets (Figure 2B).
Autophagy is enhanced when murine (Hubbard et al., 2010;
Kabat et al., 2016; Watanabe et al., 2014; Botbol et al., 2015;
Yang et al., 2013) and human T cells are activated and prolifer-
ating (Watanabe et al., 2014). If the liver housed a larger propor-
tion of proliferating T cells, this may explain their higher
autophagy levels. The percentage of CD8+ T cells expressing
Ki67, a marker of recent cell cycling, was not significantly higher
on T cells within the liver than it was in the circulation (Figure 2C;
Pallett et al., 2017). We confirmed in humans that ex vivo prolif-
erating (Ki67+) CD8+ T cells in both blood and liver had higher
autophagy levels than Ki67 CD8+ T cells (Figures 2D and 2E)
and that recently activated (Figure 2E) and dividing human
CD8+ T cells (Figure 2F) showed upregulated autophagy, as
has been shown previously in mice (Hubbard et al., 2010; Pua
et al., 2007). We conclude that T cells in the liver show enhanced
Figure 1. Intrahepatic lymphocytes Are Char-
acterized by High Ex Vivo Autophagy Levels
(A) The dimensionality reduction algorithm tSNE was
applied to flow cytometry data (single cell expression
values from total live CD45+ singlet lymphocytes
for: CD3, CD4, CD8a, CD19, CD103, CD69, pan-ɣd
T cell receptor (TCR), pan-ab TCR, CD161, CD56,
and LC3) to generate a two-dimensional map of
lymphocytes from paired PBMC (left) and IHL (mid-
dle) samples from two individuals colored by intensity
of LC3 or by lymphocyte subset (right; example
gating Figure S1A).
(B) Histograms (gated on CD8+; ± bafilomycin A1
[bafA1] treatment, 0.1 mM; FMO for LC3) and sum-
mary data for LC3 staining of paired peripheral
(PBMCs; black) and intrahepatic (IHLs; red) T cells (23
biological replicates).
(C and D) Example of gating, histograms, and sum-
mary data for LC3 stainingofCD161, CD161mid, and
mucosal-associated invariant T cells (MAITs; CD161hi
Va7.2+; 11–14 biological replicates) (C) and CD19+ (B
cells) and CD56+ (NK cells) lymphocytes (10 biolog-
ical replicates) (D).
Cells were treatedwith bafA1 unless otherwise stated
(unblocked data in Figure S1) (A, C, and D). Wilcoxon
paired t test (B and D). For pairwise multiple com-
parisons (within PBMC/IHL comparisons) Friedman
test (ANOVA) with Dunn’s post hoc test (C). For
multiple unpaired comparisons (between PBMC and
IHL for a given subset) Kruskal-Wallis (ANOVA) with
Dunn’s post hoc test. Bars atmean (B, C, and D). *p <
0.05, **p < 0.005, ****p < 0.0001.autophagy levels relative to their counterparts in the blood,
which cannot be accounted for solely by their differentiation or
proliferation status.
Autophagy Levels Are Highest in T Cells That Reside in
the Liver
We have recently defined a population of CD8+ T cells that are
retained and maintain functionality in the immunosuppressive
liver environment (Pallett et al., 2017). These liver-resident
CD8+ T cells are distinguished by expression of the tissue-reten-
tion marker CD69 (a sphingosine 1-phosophate receptor-1Cell Rantagonist), with or without CD103
(integrin-aE, which in combination with
integrin-b7 can bind to E-cadherin on
endothelial cells and hepatocytes).
CD69+CD103+/ TRM cells are enriched
in the liver, with CD69+CD103+ being
completely absent from the blood
(example plot in Figure S1A; Pallett
et al., 2017; Stelma et al., 2017).
We assessed the rate of autophagy
within the liver-resident CD8+ TRM
compared with non-resident, liver-infil-
trating T cells (CD69CD103) transiting
through the liver at the time of sam-
pling. By looking more closely at thesubpopulations of CD8+ T cells in the tSNE output, we
observed that CD69+CD103+/ CD8+ TRM cells clustered in
areas of high-LC3 expression, relative to all PBMCs and
IHLs (Figure 3A). Extending those data to a cohort of 38
paired human blood and liver samples, a stepwise increase
in autophagy levels was seen from CD69CD103 liver-infil-
trating, to CD69+CD103, to CD69+CD103+ liver-resident
memory CD8+ T cells, suggesting that rates of autophagy
are greatest in populations of T cells that reside long term in
the liver (Figures 3B and 3C; ratio blocked versus unblocked
in Figure S2A).eports 30, 687–698, January 21, 2020 689
Figure 2. High Autophagy Level of Intrahepatic T Cells Is Not a Result of a Difference in Differentiation Status or Recent Proliferation
(A) Example plot of CD45RA versus CCR7 staining (CD8+ T cells) from a PBMC or IHL sample and summary data for LC3 staining of CD8+ T cell memory subsets
(PBMC, 9; and IHL, 15, biological replicates; box whisker, Tukey).
(B) Comparison of LC3 staining of CD8+ T cell memory subsets between paired PBMC and IHL samples (9 biological replicates; box whisker, Tukey; outliers
shown as dots).
(C) Ex vivo CD8+ T cell Ki67 expression.
(D and E) Example plots (CD8+ T cells, PBMC) (D) and summary data for LC3 staining on Ki67 and Ki67+ CD8+ T cells (E) in PBMCs and IHLs ex vivo (10 biological
replicates) or after anti-CD3/CD28 stimulation (overnight, 0.5 mg/mL each; three biological replicates) in PBMCs.
(F) Histograms showing the dilution of CellTrace Violet (CTV), LC3 staining, and co-staining of LC3 and CTV on CD8+ T cells after 5 days of stimulation with anti-
CD3/CD28 (red), compared with that without stimulation (gray) or without CTV staining (black; two representative biological replicates of five, PBMCs).
Cells were treated with bafA1 (A–F). Friedman test (ANOVA) with Dunn’s post hoc test for pairwise multiple comparisons (A and B). Mann-Whitney t test (C and E).
*p < 0.05, **p < 0.005, ***p < 0.001.We next tested whether the ex vivo difference in autophagy
rates in human liver-resident memory CD8+ T cells could be
validated by two further markers of autophagosomes and by im-
aging flow cytometry. We found that CD8+ TRM cells are also690 Cell Reports 30, 687–698, January 21, 2020characterized by higher autophagy levels when quantifying the
relative accumulation of the autophagosome-associated cargo
protein sequestosome-1 (p62, SQSTM1; Figure S2B) and the
use of the autophagic vesicle-specific dye Cyto-ID (Figures
Figure 3. Autophagy Levels Are Highest in T
Cells that Reside in the Liver
(A) tSNE was applied to flow cytometry data (sin-
gle-cell expression values from total live CD45+
singlet lymphocytes for CD3, CD4, CD8⍺, CD19,
CD103, CD69, pan-ɣd TCR, pan-ab TCR, CD161,
CD56, and LC3) to generate a two-dimensional
map of lymphocytes from paired PBMC (left)
and IHL (middle) samples from two individuals.
Cells are colored by lymphocyte subset
(left; example gating in Figure S1A) and by
intensity of LC3 staining for PBMCs and IHLs
combined (middle). CD8+ TRM cells (pan-ab
TCR+CD3+CD8+CD69+CD103+/) and MAITs
(CD3+CD161hiTCR-Va7.2+) are plotted (right).
(B and C) Representative plots (B) and cumulative
data (C) of LC3 staining on liver-resident
(CD69+CD103 [black] and CD69+CD103+ [red]
subsets) and non-resident liver infiltrating T cells
(CD69CD103 [gray]) in the human liver or
CD69CD103 T cells in the blood (white). Bars at
geometric mean (see also Figure S2; PBMC, 21;
and IHL, 38, biological replicates).
(D) Example images of single liver-resident
(CD69+CD103+) or recirculating (CD69CD103)
CD8+ T cells from a human perfusate sample by
ImageStream (see also Figure S3; representative
of three biological replicates). L/dead, fixable live
dead.
(E) Mean intensity of LC3 staining of TRM cells and
recirculating intrahepatic CD8+ T cells by Image-
Stream.
(F) The percentage of TRM cells and recirculating
intrahepatic CD8+ T cells that contained two or
more LC3 puncta by ImageStream.
(G) Representative ex vivo dextramer staining,
histograms of LC3 staining, and summary data
for LC3 staining of HBV-specific (blue; see
Method Details for panel of HBV dextramers
targeting HBV core, surface, and polymerase),
CMV-specific (black; pp65485-504 HLA-A*02, NLVPMVATV) and total CD8+ T cells (white), in PBMCs from patients chronically infected with HBV (Table S1; 10
biological replicates).
Representative examples from one of two technical replicates (E and F). Cells treatedwith bafA1 (unblocked data in Figure S2) (A–G). Kruskal-Wallis (ANOVA) with
Dunn’s post hoc test for multiple unpaired comparisons (C). Friedman test (ANOVA) with Dunn’s post hoc test multiple paired comparisons (C, E, and F).Wilcoxon
t test (G). *p < 0.05, **p < 0.005, ****p < 0.0001.S2C and S2D; example plot in Figure S1A). To directly visualize
autophagosomes within T cells, we then used a recently devel-
oped autophagy assay employing imaging flow cytometry (Im-
ageStream; Klionsky et al., 2016; Phadwal et al., 2012; Puleston
et al., 2014) to visualize LC3 within autophagosome puncta
(gating strategy and staining controls in Figure S3). We
confirmed by ImageStream that there was higher per-cell me-
dian fluorescence for LC3, representing a higher total number
of autophagosomes (example cell images in Figure 3D), for
liver-resident T cells relative to peripheral CD8+ T cells or liver-
infiltrating T cells (Figure 3E). We then quantified distinct auto-
phagosomes as LC3+ puncta within T cells and showed that
most TRM cells contained multiple autophagosome puncta,
whereas recirculating CD8+ in the liver mainly contained one or
no autophagosomes (Figure 3F). Taken together, these data,
based on four different approaches, showed enhanced auto-
phagy levels in CD8+ T cells that are resident versus those infil-
trating the liver or in the periphery.Using PBMCs isolated from patients chronically infected
with HBV (Table S1), we next asked whether a population of
memory T cells that has been primed and/or encountered
cognate antigen within the liver would also be imprinted with
enhanced autophagy levels. We stained PBMCs with major
histocompatibility complex (MHC)-class I dextramers loaded
with peptides corresponding to immunodominant HBV and
cytomegalovirus (CMV) epitopes in HLA-A*02+ patients and
compared the autophagy levels of total CD8+ T cells, HBV-
specific T cells, and a population of memory T cells directed
against a control virus (CMV specific). HBV-specific T cells
showed a higher level of autophagy than total CD8+ T cells
or CMV-specific T cells assayed in the same patients (Fig-
ure 3G). The small population of HBV-specific memory
T cells with high levels of autophagy that persists in patients
chronically infected with HBV may represent a pool of
T cells that have enhanced autophagy levels imprinted on
them when in the liver. Taken together, these data show thatCell Reports 30, 687–698, January 21, 2020 691
Figure 4. Enhanced Autophagy Levels Are
Linked to Effector Function and Mitochon-
drial Fitness in Human T Cells
(A) Example plots of IFN-g, LC3, granzyme B
(GzB), and perforin (perf; gated on CD8+ T cells)
and histograms of LC3 staining for PBMC ex vivo
or after anti-CD3/CD28 stimulation (3 days; see
also Figure S3).
(B) LC3 staining of CD8+ T cells from unstimulated
PBMCs (IFN-g), IFN-g and IFN-g+ CD8+ T cells
after anti-CD3/CD28 stimulation (3 days; eight
biological replicates).
(C and D) LC3 staining on GzB and perf-express-
ing CD8+ T cells ex vivo (C) and after anti-CD3/
CD28 stimulation (D) (3 days; eight biological
replicates; box whisker, Tukey).
(E) Example mitochondrial staining of CD8+ T cells
in blood (PBMCs; black) and liver (IHLs; red) and
summary data for the ex vivo percentage of total
CD8+ T cells with depolarized mitochondria (mi-
toTracker deep red [MtDR]lo; see also Figure S4;
PBMCs, 10; and IHLs, 15 biological replicates).
(F) Ex vivo percentage of CD8+ TRM cell subsets in
the liver with depolarized mitochondria (14 bio-
logical replicates; box whisker, Tukey; outliers
shown as dots).
(G) The percentage of total CD8+ T cells or CD8+
TRM cell subsets with depolarized mitochondria
after overnight culture of IHLs with DMSO (un-
treated), MRT68921 dihydrochloride (10 mM),
bafA1 (0.1 mM), or reagent A (chloroquine
diphosphate, 1:1000, FlowCellect LC3 kit; 13–15
biological replicates).
Cells were treated with bafA1 (A–D). Bars at mean
(B, E, and G). Friedman test (ANOVA) with Dunn’s
post hoc test for pairwisemultiple comparisons (B,
C, D, and F). Kruskal-Wallis test with Dunn’s post
hoc test for unpaired multiple comparisons (G).
Mann-Whitney unpaired t test for total CD8+
PBMCs versus IHLs (E). Wilcoxon paired t test for
untreated versus that treated with MRT68921 (G).
Bars at mean (E and G). *p < 0.05, **p < 0.005,
***p < 0.001, ****p < 0.0001.autophagy levels are highest in T cell subsets resident or
encountering antigens within the liver.
Enhanced Autophagy Levels Are Associated with
Enhanced Effector Function and Mitochondrial Fitness
in T Cells
We next investigated the functional consequence of enhanced
autophagy for human CD8+ T cells to determine whether the692 Cell Reports 30, 687–698, January 21, 2020T cells that gain specific effector func-
tions on activation are also those that
have the highest induction of autophagy.
Upon in vitro activation, CD8+ T cells
that produced IFN-g also showed an
enhanced rate of autophagy (Figures 4A
and 4B; LC3 staining and cytokine
release controls are shown in Figure S3E;
LC3 staining by FlowCellect kit was per-
formed in parallel to brefeldin A treatmentand permeabilization with a transcription factor staining kit to
confirm that autophagosome quantitation was equivalent by
intracellular staining, r = 0.9404 p < 0.0001 for CD8+ T cells; Fig-
ure S3F). Without stimulation, T cells with cytolytic potential
ex vivo also had higher autophagy levels than did T cells that
lacked perforin or granzyme B (GzB) expression (Figure 4C).
When stimulated, the expanded population of CD8+ T cells ex-
pressing cytolytic markers showed an increase in autophagy,
and T cells that co-expressed GzB and perforin were those with
the highest autophagy levels (Figure 4D). There is, therefore, an
association on a per-cell basis between the upregulation of auto-
phagy by human CD8+ T cells upon activation and the acquisi-
tion of T cell effector functions.
Murine T cells lacking autophagy because of ATG7 deletion
have been shown to accumulate mitochondrial mass and ROS
(Puleston et al., 2014); a higher level of autophagy promotes
removal of depolarized mitochondria and ROS in T cells (mitoph-
agy) (Schlie et al., 2015; Jia and He, 2011; Pua et al., 2009;
Stephenson et al., 2009; Hubbard et al., 2010). This may be
particularly important in an oxygen-deprived environment,
such as the liver, in which mitochondrial damage and ROS accu-
mulation can be high, as has been shown for HBV-specific T cells
(Fisicaro et al., 2017; Schurich et al., 2016).
To assessmitochondrial fitness, we co-stained T cells withMi-
toTracker Deep Red (MtDR), a polarization-sensitive dye that
only stains functional polarized mitochondria, and MitoTracker
green (MtG), which stains all mitochondria (Puleston, 2015;
Zinser et al., 2018). Dying T cells in the liver and blood (defined
as fixable live/dead+) were almost exclusively MtDRlo, consistent
with the high rates of depolarized mitochondria expected in this
population (Figure S4A). Within the live lymphocyte gate, a
larger proportion of total CD8+ T cells had depolarizedmitochon-
dria in the liver than in the blood (Figure 4E). When dissected
by expression of tissue-residency markers, the liver-infiltrating
CD69CD103 fraction had the greatest burden of dysfunctional
mitochondria (Figure 4F), in line with their lower autophagy rate
compared with TRM cells. When autophagy was blocked over-
night with the autophagy-specific inhibitor MRT68921 dihydro-
chloride (inhibitor of Unc-51-like autophagy-activating kinase,
blocking autophagosome nucleation; Petherick et al., 2015), all
liver T cell subsets accumulated depolarized mitochondria,
underscoring the importance of this pathway for removal of
damaged mitochondria, as has been shown for murine T cells
(Figure 4G; Pua et al., 2009; Watanabe et al., 2014; Stephenson
et al., 2009). Enhanced accumulation of depolarized mitochon-
dria was also seen when using endosomal-acidification inhibi-
tors to block autophagosomal digestion (bafA1 or reagent A,
FlowCellect Kit; Figure 4G). Consistent with their lower baseline
autophagy levels, with each autophagy inhibitor it was again the
infiltrating, rather than resident, fraction of intrahepatic CD8+
T cells that accumulated the highest levels of depolarized mito-
chondria (Figure 4G).
One potential caveat to these findings is that a subpopulation
of CD8+ TRM cells with the ability to efflux fluorescent dyes, such
as MtG, has been previously described in the human lung,
spleen, and bone marrow (Kumar et al., 2018). We found that
efflux+ T cells are also present in the human liver and are en-
richedwithin theCD69+CD103+/ TRM cell fractions (Figure S4B).
However, when efflux pump inhibitors verapamil or cyclosporin
A (CSA) were used, the percentage of depolarized mitochondria
(MtDRlo) did not change (Figure S4C), showing that efflux+ TRM
cells were retained within the MtDR+ gate, independent of dye
efflux. Therefore, the differences in depolarized mitochondria
that we observed were not simply due to differential dye efflux.
The accumulation of depolarized mitochondria can also be a
general feature of apoptosis; however, the viability of lympho-cytes treated with autophagy inhibitors overnight was not greatly
reduced relative to untreated cells (Figure S5). This suggests that
the accumulation of depolarized mitochondria was a conse-
quence of a reduction in mitophagy and not secondary to any
toxicity of the autophagy inhibitors.
Overall, these data suggest that the liver is an environment in
which mitochondrial damage is high, and where persistent high
levels of mitophagy may be required for T cells to adapt to resi-
dency within this milieu.
In Vitro-Induced TRM Cells Have a High Level of
Autophagy, and TRM Cell Induction Is Limited When
Autophagy Is Blocked
Tissue-resident T cells have only recently been recognized, and
the mechanism by which residency is imprinted on T cells in vivo
has yet to be fully decoded. We and others have previously
tested a range of cytokines and T cell stimulations and identified
an efficient protocol to induce CD8+ TRM cell phenotype T cells
in vitro from human PBMCs using sequential exposure to IL-15
and then TGF-b (Pallett et al., 2017; Sowell et al., 2017; Mackay
et al., 2015), two prototypical liver cytokines. These de novo
‘‘induced residency’’ CD8+ TRM cells express both CD69 and
CD103 and have several other characteristics of human liver-
resident T cells (e.g., expression of CXCR3, CXCR6, and a Blim-
phiEomeslo phenotype; Pallett et al., 2017). Here, we used this
protocol to assess whether in vitro-induced residency is also
accompanied by enhanced levels of autophagy, consistent
with TRM cell staining ex vivo. Sequential exposure to IL-15 and
TGF-b, shown to optimally induce de novo CD8+
CD69+CD103+ TRM cells from PBMCs (Pallett et al., 2017) was
also able to efficiently upregulate autophagy, with the latter ef-
fect attributable to IL-15 (Figures 5A and 5B). We confirmed
that IL-15 alone induced autophagy in a dose-dependent
manner in CD8+ T cells either within PBMCs or after isolation;
this autophagy induction could be blocked with an anti-IL-15
monoclonal antibody (Figure 5B).
IL-15 is constitutively expressed by several liver-resident cell
types, including hepatic stellate cells (HSCs) (Golden-Mason
et al., 2004; Winau et al., 2007; Zhou et al., 2018) and liver
macrophage populations (Golden-Mason et al., 2004). To test
whether a liver-resident cell population known to produce IL-
15 could recapitulate the high levels of T cell autophagy
observed in liver TRM cells, we co-cultured peripheral T cells
with primary HSCs isolated from the healthy margins of liver
resections. A trend toward a dose-dependent induction of
T cell autophagy was observed after incubation of T cells with
HSCs, and this induction could be partially blocked by the
addition of recombinant human IL-15Ra (Figure 5C), supporting
a potential role for HSC-derived IL-15 in driving the high T cell
autophagy we observed in human IHLs.
To investigate whether the induction of autophagy was a
prerequisite for the acquisition of a TRM cell profile, we used
inhibitors of autophagy during the cytokine TRM cell induction pro-
tocol. The autophagy inhibitors MRT69821 dihydrochloride and
3-MA (3-methyladenine; types I and III phosphatidylinositol
3-kinases inhibitor; Mocholi et al., 2018) were able to partially
block the induction of autophagy seen during in vitro TRM cell
induction (Figures 5D and 5E). Crucially, the reduction inCell Reports 30, 687–698, January 21, 2020 693
Figure 5. De Novo-Induced TRM Cells Have
a High Level of Autophagy, and TRM Cell In-
duction Is AbrogatedWhenAutophagy Is In-
hibited
(A) LC3 staining of CD8+ T cells after 6 day
of PBMC culture with the following cytokines:
recombinant human TGF-b (rhTGF-b, 50 ng/ml)
at day 0, rhIL-15 (50 ng/mL) at day 0,
sequential rhIL-15 at day 0 then rhTGF-b
at day 3 (bars at median; 9–24 biological repli-
cates).
(B) LC3 staining of CD8+ T cells after 3 days of
PBMC culture or isolated CD8+ T cells with rhIL-15
alone (0.05-50 ng/mL) or with anti-IL-15 blocking
antibody (0.05-5 mg/mL; three to seven biological
replicates).
(C) LC3 staining of CD8+ T cells after 3 days of
PBMC co-culture with isolated primary human
hepatic stellate cells (pHSCs; seven biological
replicates) and in the presence of IL-15 blocking
with rhIL-15Ra-Fc chimera (0.01 mg/mL; four
biological replicates). Box whisker, Tukey; outliers
shown as dots.
(D) Example plots of TRM cell induction and his-
tograms of LC3 staining after 6 days of culture
with sequential rhIL-15 at day 0; then, rhTGF-b at
day 3 with and without autophagy inhibitors:
MRT68921 dihydrochloride (1 mM) and 3-MA (3-
methyladenine; 0.5 mM).
(E and F) LC3 staining (E) and magnitude of the
induced CD69+CD103+ TRM cell population (F) as
a percentage of CD8+ T cells after 6 days of cul-
ture with and without autophagy inhibitors (10–32
biological replicates).
(G) Phenotypic changes in total CD8+ T cells after
stimulation with anti-CD3/CD28 (3 days) with and
without the autophagy inhibitors (six biological
replicates).
Cells were treated with bafA1 (A, B, and D–G).
Kruskal-Wallis (ANOVA) with Dunn’s post hoc test
or multiple unpaired comparisons (A, E, and F). Friedman test (ANOVA) with Dunn’s post hoc test for pairwise multiple comparisons (B and C). One-way ANOVA
with Holm-Sidak post hoc test multiple paired comparisons unstimulated versus other treatments (G). *p < 0.05, **p < 0.005, ***p < 0.001, ****p < 0.0001.autophagy achieved with these inhibitors abrogated the acquisi-
tion of molecules critical for tissue retention (Figures 5F and S5D).
The observed abrogation of TRM cell induction was not attrib-
utable to autophagy inhibitors rendering T cells completely unre-
sponsive to stimulation or to a loss of T cell viability. Inhibition of
autophagy selectively prevented in vitro TRM cell induction by IL-
15/TGF-b without causing a significant reduction in the number
of liver-infiltrating CD69CD103 T cells (Figure S5D) or in TRM
cell viability (Figure S5E). T cells could still become activated
(co-expression of CD38 and PD-1) and differentiate into effec-
tors (CD27+CD28) when T cell receptor (TCR)-stimulated in
the presence of autophagy inhibitors (Figure 5G). Overall, these
data suggest that IL-15-driven induction of T cell autophagy
may be specifically required for tissue-residency programming.
DISCUSSION
Using high-dimensional flow and imaging cytometry applied to
fresh human liver samples, we show a link between greater
use of autophagy and tissue-resident memory. We show that694 Cell Reports 30, 687–698, January 21, 2020enhanced autophagy is required for optimal acquisition of tissue
residency in vitro and for maintenance of T cell mitochondrial
fitness, and may be imprinted on liver-resident CD8+ T cells by
the prototypic hepatic cytokine IL-15.
Autophagy has an active role in the functionality and differen-
tiation of diverse lymphocyte subsets, in particular, for long-lived
and quiescent cells (Riffelmacher et al., 2018; Clarke et al., 2018;
Zhu et al., 2018). Complete ablation of autophagy in total murine
T cells results in defective homeostasis or responsiveness to
stimulation (Schlie et al., 2015; Puleston et al., 2014; Stephenson
et al., 2009; Pua et al., 2009; Jia and He, 2011; Hubbard et al.,
2010). In particular, autophagy-deficient memory T cells are
depleted, either because they fail to survive the transition from
effector to memory T cells or because they need autophagy
for their maintenance (Schlie et al., 2015; Xu et al., 2014; Pules-
ton et al., 2014; Murera et al., 2018; DeVorkin et al., 2019);
however, how varied levels of autophagy affect T cell survival,
functionality, and differentiation and the importance of auto-
phagy for human T cell subsets, in particular tissue-resident
CD8+ T cells had not, to our knowledge, been considered.
Not only were autophagy levels high in total CD3+, CD4+, or
CD8+ T cells isolated from human liver samples, but within the in-
trahepatic compartment, the T cells with the highest level of
autophagy were those that expressed the tissue-retention
markers CD69+ and CD103+ (Pallett et al., 2017). We demon-
strated that differences between T cells in the liver and blood
were not solely due to differences in intrahepatic T cell
morphology, memory subset composition, or levels of activation
and proliferation.
Conceptually, howmight human T cells in the liver benefit from
enhanced autophagy levels? We first tried to address this by
asking whether the levels of autophagy in T cells were linked to
their functional profile, as has been suggested in mice. In mice,
autophagy may be transiently reduced immediately after T cell
activation, but effector T cells show a higher level of autophagic
flux than do naive T cells, and complete abrogation of autophagy
has a profound effect on T cell survival and transitioning to
long-lived memory T cells (Xu et al., 2014). We confirmed that
autophagy was increased in effector T cells 3–5 days after
TCR-mediated activation and further demonstrated that on a
per-cell basis, the acquisition of T cell effector function only
occurred in accordance with increased rates of autophagy.
Ex vivo expression of cytolytic mediators or the proliferation
marker Ki67 correlated with higher levels of autophagy. Higher
levels of autophagy may, therefore, be required to allow a
T cell to respond to stimulation or to switch on and retain effector
functions. This is supported by murine data showing that anergy
is induced in CD4+ T cells if autophagy is inhibited at the time of
TCR-mediated stimulation (Mocholi et al., 2018). This was also
the case in our in vitro TRM cell-induction model, which showed
that the pro-proliferative cytokine IL-15 drives CD8+ T cell auto-
phagy in a dose-dependent manner.
Autophagy is the main mechanism by which damaged, depo-
larized mitochondria are selectively targeted to the lysosome for
their removal (mitophagy; Villa et al., 2018), and this pathway has
been shown to be important in neutrophils (Riffelmacher et al.,
2018), B cells (Clarke et al., 2018), and global murine T cells
(Pua et al., 2009; Stephenson et al., 2009; Jia and He, 2011; Mur-
era et al., 2018). T cell-specific autophagy knockout models uni-
formly demonstrate an increase in depolarizedmitochondria and
ROS, leading to increased T cell death (Murera et al., 2018; Jia
and He, 2011; Pua et al., 2009; Stephenson et al., 2009; Wata-
nabe et al., 2014; Schlie et al., 2015). Mitochondria can become
damaged when defective mitochondrial proteins or ROS accu-
mulate (reviewed in Haynes et al., 2013). The liver is unique in
that it receives most of its blood as deoxygenated venous blood
(Carreau et al., 2011) and is characterized by high levels of oxida-
tive stress (Huang et al., 2017; Garcı´a-Ruiz and Ferna´ndez-
Checa, 2018). Of note, mitochondrial defects and reduced
survival are also a characteristic of autophagy-deficient hepatic
stellate cells (Herna´ndez-Gea et al., 2012).
Our study showed an accumulation of depolarized mitochon-
dria in intrahepatic T cells ex vivo, in keeping with the high oxida-
tive stress milieu. Pharmacological inhibition of autophagy in hu-
man T cells can also lead to an accumulation of damaged
mitochondria, suggesting a role for mitophagy in the mainte-
nance of human T cell homeostasis. Liver-resident T cells with
high basal autophagy were better able to maintain mitochondrialfitness. Our data suggest that non-resident T cells that infiltrate
the liver are less-well adapted to the milieu and, without the
requisite high basal autophagy levels, are more susceptible to
mitochondrial depolarization. Similarly, we found that MAITs,
another liver resident population (Salou et al., 2019) previously
shown to maintain tight control of depolarized mitochondria
(Zinser et al., 2018), are also characterized by high autophagy
levels. Overall, these observations support the concept that tight
mitochondrial quality control is essential for T cell homeostasis in
the liver and that this is provided by enhanced autophagy levels.
Future work is needed to investigate whether the depolarized
mitochondria characteristic of intrahepatic T cells are accompa-
nied by a high burden of cytosolic or mitochondrial ROS and
whether ROS scavengers can abrogate their dependence on
autophagy (Fisicaro et al., 2017; Pilipow et al., 2015). Alterna-
tively, the requirement for mitophagy to replace damaged mito-
chondria may provide a ROS-independent mechanism by which
autophagy adapts T cells to tissue residence.
A loss of control of mitochondrial fitness is a characteristic of
exhausted T cells (Bengsch et al., 2016), in particular, HBV-spe-
cific T cells (Schurich et al., 2016). Exhausted HBV-specific
T cells could be partially rejuvenated in vitro by correcting this
mitochondrial defect with mitochondria-specific ROS scaven-
gers (Fisicaro et al., 2017). Using MHC class I multimers, we
were able to show that HBV-specific T cells circulating in chron-
ically infected patients, which would have been primed and/or
exposed to cognate antigens in the liver, had a higher level of
autophagy when assayed in the blood relative to total CD8+
T cells or CMV-specific T cells. This suggested that virus-spe-
cific T cells can have enhanced autophagy levels imprinted on
them by the environment in which they encounter antigens.
We investigated the autophagy-inducing properties of the pro-
totypic liver cytokine IL-15 (Golden-Mason et al., 2004; Jiao et al.,
2016), which can be produced by HSCs and hepatic macro-
phages (Golden-Mason et al., 2004; Winau et al., 2007; Zhou
et al., 2018). IL-15 has been linked to the maintenance and
imprinting of the TRM cell phenotype (Holz et al., 2018; Mackay
et al., 2015) and to autophagy induction in NK and NKT cells
(Zhu et al., 2018). In this study, we show that IL-15 can directly
induce autophagy in human T cells and that TRM cell induction
in vitro is dependent on autophagy. IL-15 has also been used for
optimal expansion of antigen-specific T cells in vivo in melanoma
models (Zeng et al., 2005), for stem-cell-like chimeric antigen re-
ceptor T (Tscm) cells (Hurton et al., 2016), and is crucial for persis-
tence of inflationary MCMV-specific T cells (Baumann et al.,
2018). We have previously shown that IL-15, in combination with
IFN-a, can restore T cell effector function and proliferative capac-
ity in exhaustedHBV-specific T cells in vivo formice and in vitro for
humans (Di Scala et al., 2016). Whether autophagy is involved in
shaping T cell differentiation and functionality in these settings
should be investigated. Taken together, our data suggest that
IL-15 or other means of inducing T cell autophagy may constitute
a useful strategy to promote highly functional T cells with the ca-
pacity to reside in the liver and resistmitochondrial depolarization,
for example, in the optimization of adoptive T cell therapy for he-
patocellular carcinoma (HCC) (Qasim et al., 2015).
In summary, upregulation of autophagy in human liver-
resident CD8+ memory T cells drives the acquisition ofCell Reports 30, 687–698, January 21, 2020 695
tissue-retention markers and protects against mitochondrial de-
polarization to optimize effector function. We demonstrate the
capacity of the prototypic hepatic cytokine IL-15 to induce auto-
phagy and suggest this imposes a cell-intrinsic adaptation to the
liver niche on tissue-resident memory T cells.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Subjects and recruitment
This study was approved by the local ethical boards of London-Brent (Research Ethics Committee reference number 16/LO/1699)
and Brighton and Sussex (Research Ethics Committee reference number 11/LO/0421). Each participant gave written informed con-
sent before inclusion. All storage of samples obtained complied with the requirement of the Data Protection Act 1998 and the Human
Tissue Act 2004, issued by the UK parliament. The influence of gender of human subjects used in this study was only considered for
data in Figure 4G, where significant inter-individual variation was observed. No influence of gender was seen (Mann-Whitney t test
female versus male p = 0.57 not significant). The gender of participants was not routinely collected with anonymised clinical data for
healthy volunteers and tissue donors.
Sample collection
Resected liver tissue from the healthy margins of tumor resections (colorectal metastases, adenocarcinoma, cholangiocarcinoma,
hepatocellular carcinoma) and paired blood samples were obtained through the Tissue Access for Patient Benefit (TAPb) scheme at
The Royal Free Hospital (approved by the University College London–Royal Free Hospital BioBank Ethical Review Committee;
Research Ethics Committee reference number 11/WA/0077). Perfusion liquid was obtained from healthy livers prior to solid-organ
transplantation (Research Ethics Committee reference 11/H0720/4).
For comparison, peripheral blood samples from healthy control individuals were included within the study (approved by the South
East Coast Research Ethics Committee; Research Ethics Committee reference number 11/LO/0421; IRAS project number, 43993).
All healthy control participants used within the study were anti-HBV, anti-hepatitis C, and anti-HIV antibody negative. Sample sizes
are given in the legends for all experiments where individual data points are not shown.
METHOD DETAILS
PBMC and IHL isolation
PBMC were isolated by density centrifugation. Heparinised blood was layered on Ficoll-Hypaque Plus (GE Healthcare) or Pancoll
(Pan Biotech) and was centrifuge for 20 minutes (mins) 800 g with slow acceleration and without brake. IHL were isolated from perfu-
sion liquid by first concentrating the cells by centrifugation (300 g 10mins) and resuspension in RPMI 1640 (Thermo Fisher Scientific).
The concentrated cell suspension was then layered on Ficoll-Hypaque Plus as above.
Explanted liver tissue sections were cut into small pieces using scissors and were incubated for 30 min in 0.01% collagenase IV
(Thermo Fisher Scientific) and 0.001% DNase I (Roche) at 37C in a humidified atmosphere with 5% CO2. After enzymatic digestion,
mechanical digestion was performed using a GentleMACS (Miltenyi Biotec). After full digestion, debris was removed by passing
single cell suspension through 70 mM cell strainers (BD biosciences). Parenchymal cells were removed by centrifugation (400 g)
on a 30% Percoll gradient (GE Healthcare). Finally, IHL were isolated by density centrifugation using Ficoll-Hypaque Plus as above.
All experiments using paired IHL and PBMC were performed ex vivo on freshly isolated cells. For ImageStream experiments
frozen IHL isolated from perfusion fluid were used. All experiments using PBMC from healthy controls used frozen PBMC.
PBMC and IHL were frozen in 10% DMSO (Sigma-Aldrich) in Isopropanol containers (1C/minute) at 5-20 3 106 PBMC/ml in
cryovials. Thawing was performed by gentle agitation at 37C with rapid dilution in RPMI containing 10% fetal bovince serumCell Reports 30, 687–698.e1–e6, January 21, 2020 e3
(FBS; Sigma-Aldrich) and 0.001% DNase I. RPMI 1640 + 10% FBS, 100 U/ml penicillin/streptomycin was used for T cell culture
media (R10).
Flow cytometry – Surface, intracellular, intranuclear, and cytokine staining
Formultiparametric flow cytometry cells were plated in 96-well round-bottomed plates (200,000-1,000,000) andwashed once in PBS
(Phosphate buffered saline; Thermo Fisher Scientific) and stained with a fixable live/Dead dye (Thermo Fisher Scientific) for 20 mins
at 4C in PBS. Cells were washed again in PBS, and incubated with saturating concentrations of surface monoclonal antibodies
(mAbs) diluted in 50% Brilliant violet buffer (BD biosciences) and 50% PBS for 30 min at 4C unless stated. For surface marker
assessment alone cells were then fixed with 1% formaldehyde (Sigma-Aldrich) in PBS for 20 mins 4C and washed twice in PBS
before being analyzed on a flow cytometer.
For intracellular and intranuclear staining, after surface Ab staining cells were resuspended in fix/perm buffer (Foxp3 / Transcription
Factor staining buffer kit, fix perm concentrate diluted 1:3 in fix/perm diluent) for 45-60 mins at 4C. Cells were then washed in
1x perm buffer (10x perm buffer Foxp3 / Transcription Factor staining buffer kit diluted to 1X in ddH2O) and saturating concentrations
of antibodies against intranuclear targets were stained in 1X perm buffer for 30-45 mins 4C. Cells were washed twice in PBS then
analyzed by flow cytometry. For intracellular cytokine staining PBMC 1 hour after stimulation 1 mg/ml brefeldin A (Sigma-Aldrich) was
added and PBMCwere incubated for 16 hours at 37C in a humidified atmosphere with 5%CO2. For stimulation by CD3-crosslinking
with co-stimulation anti-CD3 and anti-CD28 (eBioscience) antibodies were diluted to 0.5 mg/ml in PBS and incubated on Nunclon
delta surface 96-well round-bottom plates (Thermo Fisher Scientific) for 1 hour. Plates were washed three times with PBS and
then cells were added in culture media.
All samples were acquired in PBS on LSRII or Fortessa X20 flow cytometers (BD biosciences) and analyzed using FlowJo (version
10.4.1 for mac, Tree Star). Single stain controls were prepared with cells where possible or anti-mouse IgG beads (BD biosciences)
and Arc-Amine reactive beads (Thermo Fisher Scientific).
Flow cytometry based LC3-I quantification
To quantify the number of autophagosome ex vivo, or the accumulation of autophagosomes (after inhibiting autophagosome degra-
dation) as proxies for the level of autophagy or autophagic flux respectively, the FlowCellect Autophagy LC3 Antibody-based Assay
Kit (Merck Millipore, now Luminex) was used (Eng et al., 2010). A proprietary permeabilisation buffer (Autophagy reagent B) is used
to selectively extract non-autophagosome associated cytosolic LC3-I; therefore, when the anti-LC3 antibody is added only the lipi-
dated form LC3-II incorporated within autophagosomes remains and is stained. The fluorescence of the anti-LC3-FITC antibody can
then be used to quantify autophagosomes.
For ex vivo assessment of autophagy levels autophagosomes were stained by flow cytometry using a fluorescently labeled anti-
LC3 antibody (clone 4E12). PBMC or IHL were washed, stained for live/dead marker and then surface markers as above. Cells were
then centrifuged at 300 g 4 mins 4C and resuspended in 50 mL autophagy reagent B permeabilisation buffer (Diluted 1:10 in ddH20)
per well and immediately centrifuged 300 g 4 mins 4C and resuspended in anti-LC3-FITC (1:20 50ul/well) diluted in assay buffer
(assay buffer concentrate is diluted 1:5 in ddH20) and incubated at 4C for 30 mins. Cells were then washed in PBS, resuspended
in 1% formaldehyde to fix for 20 mins at 4C, washed in PBS, and run on a flow cytometer.
The geometric mean fluorescence intensity (geoMFI) of LC3 ex vivo without addition of bafilomycin A1 (‘‘unblocked’’) was used to
define the basal autophagy level. To measure the accumulation of autophagosomes over time 0.1 mM bafilomycin A1 (‘‘blocked’’;
Sigma-Aldrich; diluted in DMSO; (Klionsky et al., 2016; Clarke et al., 2018; Puleston et al., 2014), was added to cell cultures overnight
(Figures 1, 2 [excluding 2F], 3, 5E, 5F, S1C, and S1D) for paired IHL and PBMC samples, or for 3 hours for all other experiments
(Figures 2F, 4, and 5; Figures 5G and 5H are unblocked) (See Figures S1B, S1C, S2, S3C and S3E for comparisons of unblocked
and bafilomycin A1 blocked staining). The ratio of geoMFI LC3 (flux) for blocked versus unblocked was calculated as follows:
(+bafA1 blocked geoMFI LC3 - unblocked geoMFI LC3) / unblocked geoMFI LC3.
When LC3 was co-stained with intracellular or intranuclear markers (Figures 2C-2E and 4A–4D) PBMC were fixed with fix/perm
buffer (Foxp3/Transcription Factor staining buffer kit) as above and anti-LC3 was added to the intracellular antibody cocktail in
perm buffer (Foxp3 / Transcription Factor staining buffer kit). Non-autophagosome associated cytosolic LC3-I is not selectively
extracted using reagent B in this protocol, therefore, a common background of LC3-I is also labeled. PBMC samples were stained
in parallel using the FlowCellect Autophagy LC3 Antibody-based Assay Kit as above or the BD Foxp3/Transcription Factor staining
buffer kit (Figure S3E and S3F). A strong positive correlation between the two staining conditions confirmed that the samples
with higher rates of autophagy by the standard protocol also had a higher level of LC3 staining when stained with the intracellular
protocol, and that the LC3-I background level was consistent across samples and treatments. Samples stained by the intracellular
protocol or FlowCellect Kit weremeasured on separate Flow Cytometers with different panels however, so direct comparisons of the
MFI magnitude cannot be made.
Intracellular staining of p62 (sequestosome 1; SQSTM1; Abcam) was performed as described in Clarke et al. 2015. IHL were incu-
bated overnight with or without bafA1 (0.1 mM). The following day after fixable live/dead stain and surface Ab staining as above cells
were fixed in 1% formaldehyde for 20 mins at 4C. Cells were then permeabilised in 1x perm buffer (10x perm buffer Foxp3 / Tran-
scription Factor staining buffer kit diluted to 1X in ddH2O) for 20 mins at 4
C and then saturating concentration of anti-p62-alexa647
was added in 1X permbuffer for 30mins 4C. Cells werewashed in 1x permbuffer and then PBS before acquiring. The ratio of geoMFIe4 Cell Reports 30, 687–698.e1–e6, January 21, 2020
p62 (sequestosome 1; SQSTM1; abcam) (flux) for blocked versus unblocked was calculated as follows: (+bafA1 blocked geoMFI
p62 - unblocked geoMFI p62) / unblocked geoMFI p62.
Flow cytometry based autophagosome quantification using Cyto-ID
Cyto-ID is a proprietary dye that includes titratablemoieties specific for staining autophagic vesicles (Enzo Lifesciences). Tomeasure
autophagy in T cells using the Cyto-ID autophagy detection kit (ENZ-51031-0050) PBMC and IHL were thawed (as above) and rested
overnight in R10 culture media in 96-well plates at 0.53 106 PBMC per well at 37C in a humidified atmosphere with 5%CO2. Plates
were centrifuged at 300 g 4mins RT and cell pellets were resuspended in pre-warmed (37’C) RPMI without phenol red (Thermo Fisher
Scientific) containing 5%FBS, 100 U/ml penicillin/streptomycin andCyto-ID dye diluted 1:4000. Cells were incubatedwith Cyto-ID at
37C in a humidified atmosphere with 5% CO2 for 30 mins before being washed with the Cyto-ID kit assay buffer diluted to 1X in
sterile distilled H2O. Cells were then stained with fixable live/dead, stained with surface antibodies, fixed with 1% formaldehyde,
and analyzed by flow cytometry as above for the surface staining protocol.
Autophagy inhibitors
MRT68921 dihydrochloride (Sigma-Aldrich; used at 1 or 10 mM for 6 day or overnight cultures respectively) is an autophagy specific
ULK1 and ULK2 kinases inhibitor (Klionsky et al., 2016; Petherick et al., 2015). 3-Methyladenine (3-MA; Sigma-Aldrich; 0.5 mM) is a
type I and III Phosphatidylinositol 3-kinases (PI-3K) inhibitor (Wu et al., 2010).
MitoTracker staining
Freshly isolated IHL and PBMCwere stained ex vivowith cell permeablemitochondrial dyes by adding themdirectly to culturemedia.
MitoTracker Deep Red FM and MitoTracker Green FM (Thermo Fisher Scientific) were added to a final concentration of 12.5 nM and
25 nM in the well respectively andwere stained for 20mins at 37C in a humidified atmosphere with 5%CO2. Cells were then washed
in PBS and stained with fixable live/dead and surface antibodies as above. Cells were left unfixed for flow cytometric analysis. For
overnight inhibition of autophagy (Figures 4G) bafilomycin A1 (0.1 mM), Reagent A (Chloroquine diphosphate, FlowCellect Autophagy
LC3 Antibody-based Assay Kit), MRT68921 dihydrochloride, or DMSO vehicle were added to R10 culture media and cells were
stained for MitoTrackers as above after 16 hours culture.
For inhibition of efflux pumps verapamil (Sigma-Aldrich; 50 uM) and cyclosporin A (Sigma-Aldrich; 50 uM) were added directly to
culturemedia with themitoTracker dyes and incubated for 20mins at 37C in a humidified atmosphere with 5%CO2 andmitoTracker
staining was as above.
ImageStream
ImageStream has been used extensively to directly image intracellular autophagosomes using fluorescently labeled anti-LC3
antibodies (Clarke et al., 2018; Klionsky et al., 2016; Phadwal et al., 2012; Sanderson and Simon, 2017; Puleston et al., 2014).
IHL and PBMC were thawed as above and were cultured overnight (16 hours) in R10 culture media supplemented with 0.1 mM
bafilomycin A1. Cells were washed and T cells were isolated using negative magnetic bead selection (panT cell isolation kit, Miltenyi
Biotec) according to themanufacturer’s instructions. T cells were collected on ice, counted, stained as above for surfacemarkers and
intracellular LC3 and fixed with 1% formaldehyde. The following panel was used: Camera 1; Ch1 Bright field, Ch2 LC3-FITC, Ch3
CD4-PE, Ch5 CD8-PerCp-Cy5.5, Ch6 SSC. Camera 2 Ch8 CD69-V500, Ch10 CD103-BV605, Ch12 Near Infrared-fixable live/dead.
Amnis ImageStreamX imaging flow cytometer (MERK-Millipore) fitted with a 603microscope objective was used for cell imaging.
Raw image files were acquired using INSPIRE software. After acquisition, a compensation matrix was applied to the data to correct
for spectral overlap. Data analysis was done using IDEAS software, displaying cells using gradient RMS for the bright field channel
to exclude out-of-focus cells and a combined area to aspect ratio dot plot ensured gating on single-cell events (see Figure S3
for gating and staining controls).
T cell proliferation assay
Frozen PBMC were thawed at 37C as described above and washed twice with sterile PBS. PBMC were resuspended in 1 mL
R10 culture media (2-10 3 106 PBMC) and 0.5 mL of 5 mM stock CellTrace violet (Thermo Fisher Scientific) was added per sam-
ple with mixing. PBMC were stained in the dark for 10 mins at 37C in a humidified atmosphere with 5% CO2. Ten-times volume
of cold R10 was added to stop the staining reaction, and cells were incubated for 5 mins on ice. Cells were washed in PBS and
incubated for 5 mins at 37C before being transferred to a new tube and were washed again in R10. CTV stained and unstained
control PBMC were plated in 48-well plates (0.5 3 106 PBMC in 0.5 mL R10) stimulated with plate bound anti-CD3/CD28
cross-linking antibodies (0.5 mg/ml each added for 1 hr in PBS, washed with 3 3 1 mL PBS) for 5 days, or in uncoated wells
(unstimulated control). At the end of the 5 days, PBMC were harvested from the 48-well plate and were transferred to a 96-
well plate and were incubated with bafilomycin A1 for 3 hours, before being washed and stained for fixable live/dead, surface
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MHC class I dextramer staining for the identification of antigenspecific T cells
HBV-specific HLA-A*02-restricted dextramers (Immudex) of the following specificities were used: core18–27 (FLPSDFFPSV),
envelope183–191 (FLLTRILTI), envelope335–342 (WLS LLVPFV), envelope338–347 (LLVPFVQWFV), envelope348–357 (GLSPTVWLSV), po-
lymerase455–463 (GLSRYVARL), and polymerase502–510 (KLHLYSHPI). CMV specific CD8
+ T cell responses were tracked using an
HLA-A*02-restricted dextramers (Immudex) loaded with the pp65495-504 (NLVPMVATV) peptide. PBMC were thawed, rested for
1 hour, and then incubated at 37C in a humidified atmosphere with 5% CO2 overnight with bafilomycin A1 (0.1 mM). PBMC were
washed in PBS and were stained with dextramers at room temperature (20mins) in PBS, washed twice in PBS before further mAb
staining as described above. During analysis, stringent gating criteria were applied with doublet and dead cell exclusion to minimize
nonspecific binding contamination. A dextramer loadedwith an irrelevant peptidewas stained in parallel to assess non-specific bind-
ing. Dextramer clouds of less than 50 cells were excluded from analysis.
In vitro Induction of TRM phenotype
For in vitro tissue-resident T cell induction, PBMC from healthy controls were incubated at 5 3 105 cells/well in 0.5 mL R10 culture
media (supplementedwith 20 IU/ml recombinant human IL2 at day 0 and day 3,Miltenyi Biotec) for 6 dayswith different combinations
of cytokines (recombinant human TGFb, rhTGFb, 50 ng/ml; recombinant human IL15, rhIL15, 50 ng/ml). On day 6 PBMC were har-
vested from the 48-well plate, transferred to a 96-well plate and were incubated with bafilomycin A1 for 3 hours, before being washed
and stained for fixable live/dead, surface Abs, and LC3 as above. Autophagy inhibitors were added throughout the culture, at day 0,
day 3, and during the 3 hour incubation with bafilomycin A1.
For 3 day cultures, PBMCwere plated in R10 culturemedia supplementedwith different doses of IL15, without IL2. On day 3 PBMC
were harvested from the 48-well plate, transferred to a 96-well plate andwere incubated with bafilomycin A1 for 3 hours, before being
washed and stained for fixable live/dead, surface Abs, and LC3 as above.
Primary human hepatic stellate cell co-culture
For extraction of primary human hepatic stellate cells (HSCs), fresh post-resection liver tissue was washed thoroughly, passed
through a tissue press and digested with DNase I (0.001%) and collagenase IV (0.01%). Cellular homogenate was filtered
through a 70 mm cell strainer and centrifuged at low speed to remove remaining parenchymal cells, then at 450 g to wash
the cells. The remaining cells were layered for density gradient isolation using Optiprep (Sigma-Aldrich). After isolation,
HSCs were suspended in Stellate Cell Medium (ScienCell Research Laboratories), plated at a density of 5 3 104 cells/cm in
tissue culture flasks and cultured at 37C in a humidified atmosphere with 5% CO2. On day 2, 3 or 4, cell debris and non-
adherent cells were removed by washing. When cultures reached confluence, cells were trypsinised and re-plated; cells
were passaged twice before freezing.
Pre-isolated HSCs were thawed and cultured in 25 cm2 tissue culture flasks in Stellate Cell Medium to approximately 90% conflu-
ence. Cells were detached with trypsin–EDTA (Thermo Fisher Scientific), re-plated in 48-well plates in Stellate Cell Media (5,000-
20,000 HSCs per well) and left for 36-48 hours to adhere. Media was removed and 53 105 PBMC/well were added with R10 culture
media and cells were co-cultured for 3 days. rhIL15Ra-Fc chimera (0.01 mg/ml; R&D systems) was added to R10 culture media with
PBMC prior to being plated on HSCs. On day 3 PBMCwere harvested from the 48-well plate, transferred to a 96-well plate and were
washed and stained for fixable live/dead, surface Abs, and LC3 as above. To confirm the differentiation status of HSCs a sample was
surface stained with ⍺-SMA and ICAM-1 at the end of the 3 days culture.
QUANTIFICATION AND STATISTICAL ANALYSIS
t-Distributed Stochastic Neighbor Embedding (tSNE) analysis
The dimension reduction algorithm tSNE was applied to concatenated flow cytometry data ( 180,000 cells) from 2 paired IHL and
PBMC samples using default parameters (iterations, 1,000; perplexity, 20; and q, 0.5) in FlowJo. tSNEwas applied to expression data
for CD3, CD4, CD8⍺, CD19, CD103, CD69, pan-ɣd T cell Receptor (TCR), pan-⍺b TCR, CD161, CD56, and LC3 after pre-gating on
single, live, CD45+ lymphocytes.
Statistical analysis
Statistical analyses were performed in either Prism (Graph-Pad Software, version 7.0e) or R version 3.2.4 using appropriate methods
as indicated in the legends (Mann-Whitney t test; Wilcoxon Signed-rank t test; Kruskal-Wallis test [ANOVA] for unpaired non-para-
metric multiple comparisons, Friedman test (ANOVA) for pairwise non-parametric multiple comparisons, both with Dunn’s post hoc
test; Spearman’s Rank Order Correlation) with significant differences marked on all figures. All tests were performed as two-tailed
tests, and for all tests, significance levels were defined as *, p < 0.05; **, p < 0.01; ***, p < 0.001; and ****, p < 0.0001.
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